Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 14

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 14
---
 Accelerate and expand a broad portfolio of TV-based product candidates to fully unlock the potential of barrier-crossing therapeutics, applying patient-informed development and driving biomarker-guided regulatory approvals.

<div align='center'>S-1</div>

3) Launch initial products targeting rare lysosomal storage diseases as a strategic foundation for expansion into common neurodegenerative conditions and other serious diseases, while building integrated capabilities for long-term growth and profitability.

#### Company Information
We were incorporated in Delaware in 2013. Our principal executive offices are located at 161 Oyster Point Blvd., South San Francisco, California 94080. Our telephone number is (650) 866-8547. Our website address is www.denalitherapeutics.com. We also use our website as a channel of distribution of important company information, including news or announcements regarding our financial performance, investor events and press releases. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. The information on, or that can be accessed through, our website does not constitute part of this prospectus supplement or the accompanying prospectus, and you should not rely on any such information in making a decision whether to purchase our common stock.

<div align='center'>S-2</div>

THE OFFERING

| Common Stock Offered by Us                                        |     | Shares of our common stock having an aggregate offering price of up to $400.0 million.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Common stock to be outstanding immediately following the offering |     | Up to 165,054,319 shares, assuming the sale of 20,833,333 shares of our common stock in this offering at an offering price of $19.20 per share, the last reported sale price of our common stock on The Nasdaq Global Select Market on February 25, 2025. The actual number of shares issued will vary depending on the sales price under this offering.                                                                                                                                                                                                                  |
| Manner of offering                                                |     | “At the market offering” that may be made from time to time through our sales agents. See “Plan of Distribution” for more information.                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Use of Proceeds                                                   |     | We currently anticipate that we will use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term marketable securities, for general corporate purposes, including research, development and manufacturing of our product candidates, working capital, capital expenditures, other corporate expenses, and acquisitions of